Volume 15, Number 10—October 2009
Letter
Nontuberculous Mycobacterium Infection and Tumor Necrosis Factor-α Antagonists
Table
Antimicrobial drug | Case report |
RIVM historic data (n = 49) |
|||
---|---|---|---|---|---|
Classification | MIC, mg/L | % Susceptible | % Resistant | ||
Isoniazid | Resistant | 10 | 0 | 100 | |
Rifampin | Susceptible | 0.2 | 4 | 96 | |
Ethambutol | Resistant | 20 | 0 | 100 | |
Streptomycin | Susceptible | <1.0 | 35 | 65 | |
Cycloserine | Susceptible | 50 | 78 | 22 | |
Prothionamide | Susceptible | <1.0 | 61 | 39 | |
Amikacin | Resistant | 10 | 29 | 71 | |
Ciprofloxacin | Resistant | 4.0 | 88 | 12 | |
Clofazimine | Susceptible | <0.5 | 92 | 8 | |
Clarithromycin | Susceptible | <2.0 | 94 | 6 | |
Rifabutin | Susceptible | <0.2 | 96 | 4 |
*All isolates submitted to the Mycobacteria Reference Laboratory, National Institute for Public Health and the Environment (RIVM), the Netherlands, January 2000–January 2007. Before January 2004, strains tested were identified by 16S rDNA gene sequencing; after January 2004, strains were identified by the Inno-LiPA assay (Innogenetics, Ghent, Belgium).
Page created: December 08, 2010
Page updated: December 08, 2010
Page reviewed: December 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.